Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 1, 2025
Data Byte
Four PDUFA dates on FDA’s February agenda
Decisions include a MAP2K1/2 inhibitor that could give Springworks a priority review voucher
BioCentury | Jul 27, 2024
Data Byte
Junshi’s PD-1 among seven new products recommended by EMA’s CHMP
Plus: Astellas’ Vyloy on track to become EU’s first CLDN18.2 therapy, and 11 products likely headed for label expansions
BioCentury | Jun 27, 2024
Product Development
Solving for the medical and business case in pediatric cancer — Day One
CEO Jeremy Bender on building a strategy for pediatric cancer therapies that serves both patients and investors
BioCentury | Apr 25, 2024
Regulation
FDA’s Ojemda approval marks Day One’s transition to commercial company
No black box warning and a broad label for the pediatric brain cancer therapy
BioCentury | Nov 16, 2023
Deals
Nov. 16 Quick Takes: Q32 takes merger route to NASDAQ via Homology deal
Plus: SpringWorks’ neurofibromatosis program headed for NDA and updates from Astellas, Propella, BMS, Merck, Nature’s Toolbox, Apollomics and Avistone
BioCentury | Jul 28, 2023
Emerging Company Profile
Genuv: multispecific cancer antibodies and neuroprotective small molecules
Seoul-based Genuv is developing a competitor to Roche’s anti-PD-1:IL-2 fusion for solid tumors; advancing a MEK inhibitor for neurodegeneration
BioCentury | Sep 8, 2022
Discovery & Translation
An inroad to bunyaviruses; plus a gene therapy for tyrosinemia and more
BioCentury’s roundup of translational news
BioCentury | Aug 27, 2021
Distillery Therapeutics
TEAD1 identified as target in a gastric cancer subtype
BioCentury | Aug 25, 2020
Product Development
Aug. 24 Quick Takes: Setbacks for Novartis, Odonate, Onconova, Tricida; plus upcoming adcomm for Alkermes, and Sinopharm’s vaccine
Novartis’ PD-1 misses in melanoma comboNovartis AG (NYSE:NVS; SIX:NOVN) said spartalizumab missed the primary endpoint of the Phase III COMBI-i trial in patients with untreated, unresectable
BioCentury | Apr 29, 2020
Product Development
Highlights from AACR’s first annual virtual meeting show mixed results for I/O combos, promise for new targets, modalities
Items per page:
1 - 10 of 104